NCT03332017 2026-02-18
ROSEWOOD
BeOne Medicines
Phase 2 Completed
Clinical Trials
10 trialsNCT04463953 2026-02-11
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
NCT04116437 2026-01-28
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
BeOne Medicines
Phase 2 Completed
NCT05068440 2025-07-25
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
BeiGene
Phase 2 Completed
NCT03145064 2024-10-26
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
BeiGene
Phase 2 Completed
NCT03206918 2024-10-26
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BeiGene
Phase 2 Completed
NCT03206970 2024-10-26
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
BeiGene
Phase 2 Completed
NCT03332173 2024-10-26
Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
BeiGene
Phase 2 Completed
NCT03520920 2024-10-26
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
BeiGene
Phase 2 Completed
NCT03846427 2024-10-26
MAGNOLIA
BeiGene
Phase 2 Completed